Alliance Data Systems: If You Don’t Like the Answer, Just Change the Question!


Citron Target on Alliance Data Systems Corp is
50% Near-Term Downside


This month Citron Research celebrates its 15th year of publication — exposing, for lack of a better term, “market inefficiencies”.

This neutral-sounding moniker is occasionally an accident … but rarely.  Most often it exploits the shallowness of Wall Street’s “insight” with management’s intentional hype, misdirection or just plain fraud.  It has become too profitable taking advantage of a bullish market environment to ever let the truth get in the way of a good story.

And then comes Citron Research

In the Case of Alliance Data Systems (NYSE:ADS), Wall Street is just now waking up to the misrepresentations that have been promulgated by ADS management.  At best, this is a mis-categorized company which should immediately be priced 40% lower.  At worst management is covering up a business that has an entirely different risk profile … and is one big credit event from derailing into a devastating downward spiral.

For the rest of the story you won’t read anywhere else, Click Here …


Cyberdyne — The Most Ridiculously Priced Stock In the World


Japanese Investors are ADVISED to

Target Price: 300¥ — 85% Downside

 With its share price ~ 2,000¥, Cyberdyne’s market cap exceeds $4 billion USD. The story of Cyberdyne MUST be told to the worldwide investment community.

Cyberdyne (TYO:7779) CEO Yoshiyuki Sankai has become a cultural icon in Japan. With his “mad scientist” appearance and his lifelong passion for robots, he has become the face of innovation and science in Japan…..But what is the truth?

 While Sankai’s creation of the HAL® (Hybrid Assistive Limb) was unique and creative in 2005 (named one of Time Magazine’s most amazing inventions of the year,) — time and competitors have eclipsed Cyberdyne; the company has yet to effectively commercialize any product. Worse, when you get past the rhetoric, propaganda and press, you find a company that is more interested in making a “Gundam Stock” rather than an underlying business of authentic value.

For the rest of the story you won’t find anywhere else, click here…

And  日本語版 

Chemours is a Bankruptcy Waiting to Happen! Chemours was Purposely Designed for Bankruptcy!


This Stock is a Zero

After 15 years of publishing, Citron can confidently state that Chemours (NYSE:CC) is the most morally and financially bankrupt company that we have ever witnessed.

Highly material events for Chemours are unfolding nearly every day in the matter of DuPont’s liabilities due to its manufacturing of C8 — also known as PFOA, and its 60 year pattern of willfully hiding its knowledge that the chemical was toxic at extremely low levels of exposure, and was being dumped into the environment at its facilities.  DuPont dumped these liabilities into spin-off Chemours.

But don’t count on Chemours to disclose these material events.  The company doesn’t even post reserves on its balance sheet for the snowballing legal and environmental costs.

The bizarre reality is that Chemours was designed to go bankruptcy.   The only question is when.

For the Rest of the Story You Won’t Read Anywhere Else … Click Here

Citron Comments on Recent Coverage of Intrexon


Dear Readers,

In August 2015, Citron tweeted that we were buying shares of Intrexon (NYSE:$XON). Upon further due diligence we sold our Intrexon, as we found none of the company’s businesses to have any imminent viability.  We should have updated our readers, but we had received almost no correspondence on the name after our tweet.

Citron wants its readers to note that we are not long shares of Intrexon, and we commend the work published on the name in a recent Seeking Alpha Commentary. We look forward to reading further commentary on Intrexon, as its businesses are too scattered with partners that Citron believes are not as they appear to be.

Lastly, what has bothered us about Intrexon is while the company has not been shy about going to investment conferences and selling stock offerings, they were never able obtain a smart money biotech shareholder. If they don’t get it, then we don’t get it. We look forward to reading more on the name.

Cautious Investing To All

Mobileye is Worth $11 per Share — Insiders Know It, Goldman Sachs Knows it, Citron Knows it, and Now You Know it!


2016 Price Target (Generous) :

Reduced to $11


Since our first report, Mobileye’s (NASDAQ:MBLY) long-term prospects have gone from bad to worse.  Insiders know it, Goldman Sachs definitely knows it … because at the end of the day,

Money Talks Bullshit Walks

In this report, we detail critical competitive landscape changes since our last report that the market has not priced in yet, but are hiding in plain sight.  Then Citron Research offers up the only intellectually honest way to value Mobileye.

It May Jump but It Will Never Fly.  

For the rest of the story you won’t read anywhere else, CLICK HERE!